Cover Image
市場調查報告書

自閉症 : 開發平台分析

Autism - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232811
出版日期 內容資訊 英文 134 Pages
訂單完成後即時交付
價格
Back to Top
自閉症 : 開發平台分析 Autism - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 134 Pages
簡介

所謂自閉症,是有社會性問題和溝通障礙,行動的限制性,反復性,定型行為等特徵的神經發育障礙,性別、家族病史、脆弱X染色體症候群、妥瑞症、癲癇等成為原因。治療方法有SSRI(選擇的血清素再吸收抑制劑)、抗憂鬱劑、抗精神病藥、鎮靜劑等的給藥。

本報告以全球自閉症治療藥的開發平台為主題,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

自閉症概要

治療藥的開發

  • 自閉症開發中產品:概要
  • 自閉症開發中產品:比較分析

自閉症:正在開發的治療藥:各企業

自閉症:正在開發的治療藥:各大學、研究機關

自閉症:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

自閉症:開發中的產品:各企業

自閉症:開發中的產品:各大學、研究機關

自閉症:開發治療藥的企業

  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc.
  • AgeneBio Inc.
  • APeT Holding BV
  • Berg LLC
  • BioCrea GmbH
  • BrainStorm Cell Therapeutics Inc.
  • Cellceutix Corporation
  • Confluence Pharmaceuticals LLC
  • Curemark, LLC
  • Domain Therapeutics SA
  • F. Hoffmann-La Roche Ltd.
  • Heptares Therapeutics Limited
  • Intra-Cellular Therapies, Inc.
  • Luc Therapeutics, Inc.
  • MedDay
  • Omeros Corporation
  • 大塚集團
  • Retrophin Inc.
  • Sage Therapeutics, Inc.
  • Saniona AB
  • 大日本住友製藥

自閉症:治療藥的評估

  • 單劑治療藥
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (dekisutorometorufan + quinidine sulfate)
  • ADX-71441
  • ADX-88178
  • Aripiprazole
  • Carbetocin
  • CM-AT
  • 自閉症用藥物
  • 組織胺二鹽酸鹽
  • HTL-14242
  • ITI-007
  • KM-391
  • 哲思(Geodon)
  • MD-1103
  • niacinamide CR
  • oxytocin
  • RG-7314
  • SF-999
  • SGE-872
  • 中樞神經系統障礙治療用GABRA5 受體激動劑
  • 自閉症治療用 GABAA 受體次單元、Alpha5小分子促效劑
  • 自閉症治療用 GPR63標靶藥物
  • 自閉症、焦慮症治療用催產素標靶藥物
  • 癲癇、自閉症治療用GABAA-Beta 2 受體激動劑
  • 自閉症治療用代謝型麩胺酸受體4促效劑
  • 中樞神經系統障礙治療用 NMDA2A拮抗劑
  • 抑制劑 PI3k 自閉症、脆弱性X症候群治療用
  • 自閉症治療用/腫瘤學用 翻譯起始因子-4E抑制劑
  • SNA-1
  • 多發性硬化症、類風濕性關節炎、骨關節炎、自閉症、支氣管肺形成異常用幹細胞療法
  • 神經退化性疾病用幹細胞療法
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 注目新聞、新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8306IDB

Summary

Global Markets Direct's, 'Autism - Pipeline Review, H2 2016', provides an overview of the Autism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Autism
  • The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Autism therapeutics and enlists all their major and minor projects
  • The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Autism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Autism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Autism Overview
  • Therapeutics Development
    • Pipeline Products for Autism - Overview
    • Pipeline Products for Autism - Comparative Analysis
  • Autism - Therapeutics under Development by Companies
  • Autism - Therapeutics under Investigation by Universities/Institutes
  • Autism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Autism - Products under Development by Companies
  • Autism - Products under Investigation by Universities/Institutes
  • Autism - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aequus Pharmaceuticals Inc.
    • AgeneBio Inc.
    • APeT Holding BV
    • BioCrea GmbH
    • BrainStorm Cell Therapeutics Inc.
    • Cellceutix Corporation
    • Confluence Pharmaceuticals LLC
    • Coronis Partners Ltd.
    • Curemark, LLC
    • F. Hoffmann-La Roche Ltd.
    • GW Pharmaceuticals Plc
    • Heptares Therapeutics Limited
    • Intra-Cellular Therapies, Inc.
    • MedDay SA
    • Omeros Corporation
    • Otsuka Holdings Co., Ltd.
    • Retrophin Inc.
    • Saniona AB
    • Sumitomo Dainippon Pharma Co., Ltd.
  • Autism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dextromethorphan + quinidine sulfate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acamprosate calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carbetocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0306 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-AT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GWP-42006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • histamine dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-14242 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KM-391 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lurasidone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-1103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niacinamide CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NurOwn - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxytocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-999 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Chloride Channels for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR63 for Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Autism and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Autism - Dormant Projects
  • Autism - Discontinued Products
  • Autism - Product Development Milestones
    • Featured News & Press Releases
      • Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
      • Dec 07, 2015: Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
      • Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
      • May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
      • Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment
      • Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
      • Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
      • Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
      • Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
      • Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
      • Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism
      • May 31, 2012: Study Reports New Treatment For Irritability In Autism
      • Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism
      • Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
      • Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Autism, H2 2016
  • Number of Products under Development for Autism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Autism - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Autism - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Autism - Pipeline by AgeneBio Inc., H2 2016
  • Autism - Pipeline by APeT Holding BV, H2 2016
  • Autism - Pipeline by BioCrea GmbH, H2 2016
  • Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2016
  • Autism - Pipeline by Cellceutix Corporation, H2 2016
  • Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
  • Autism - Pipeline by Coronis Partners Ltd., H2 2016
  • Autism - Pipeline by Curemark, LLC, H2 2016
  • Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Autism - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Autism - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Autism - Pipeline by MedDay SA, H2 2016
  • Autism - Pipeline by Omeros Corporation, H2 2016
  • Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Autism - Pipeline by Retrophin Inc., H2 2016
  • Autism - Pipeline by Saniona AB, H2 2016
  • Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Autism - Dormant Projects, H2 2016
  • Autism - Dormant Projects (Contd..1), H2 2016
  • Autism - Dormant Projects (Contd..2), H2 2016
  • Autism - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Autism, H2 2016
  • Number of Products under Development for Autism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top